Pharmaceutical Product Development (PPD, Inc.) (NASDAQ: PPDI) is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. The company’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. While PPD is mainly known for conducting all aspects of drug development for its clients, it also invests directly in developing new products through its compound partnering program.
PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.
PPD is headquartered in Wilmington, N.C. The company has approximately 10,500 employees in 48 countries.
PPD operates in two main segments: development services and discovery sciences/compound partnering. PPD has also forged strategic alliances with various biopharmaceutical companies and consulting firms in key areas of drug development.
PPD provides clinical development and post-approval services for biopharmaceuticals and devices. In
This site uses cookies to give the best and personalised experience. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.
